Biogen Entered into a License Agreement with MedRhythms to Develop and Commercialize MR-004 for the Treatment of Gait Deficits in Multiple Sclerosis
Shots:
- MedRhythms to receive $3M up front & is eligible to receive ~$117.5M upon achievement of development & commercial milestones along with royalties
- The collaboration will combine MedRhythms’ digital expertise with Biogen’s leadership & global footprint to advance novel therapies for MS & address the patient's unmet needs. MR-004 is the prescription digital therapeutic that uses a combination of sensors, software & music based on rhythmic auditory stimulation
- If approved, MR-004 will become the 1st prescription digital therapeutic for gait deficit in MS. MedRhythms conducts 2 ongoing feasibility studies for MR-004 & also plans to initiate a registrational trial, based on 1st study results
Ref: Businesswire | Image: Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
